drugset
drugset / Trial / NCT07712562

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes

NCT07712562 ↗

Phase 1/2 Not yet recruiting 60 enrolled Dren Bio
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, Phase 1/2 basket study to evaluate the safety and efficacy of Dibotatug (DR-01) in adults with Bone Marrow Failure syndromes.

Timeline

Start
2026-08
Primary completion
2029-04
Completion
2030-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Dibotatug Monoclonal antibody — Intravenous

Indications

aplastic anemia bone marrow failure syndrome